Leveraging ageing models of pulmonary fibrosis: the efficacy of nintedanib in ageing
Kato K, Shin YJ, Palumbo S, Papageorgiou I, Hahn S, Irish JD, Rounseville SP, Krafty RT, Wollin L, Sauler M, Hecker L. Leveraging ageing models of pulmonary fibrosis: the efficacy of nintedanib in ageing. European Respiratory Journal 2021, 58: 2100759. PMID: 34531276, PMCID: PMC8613836, DOI: 10.1183/13993003.00759-2021.Peer-Reviewed Original ResearchConceptsEfficacy of nintedanibIdiopathic pulmonary fibrosisAged miceLung fibrosisPulmonary fibrosisElderly patientsLung functionPre-clinical efficacy studiesAged animal modelsIPF clinical trialsVital capacity declineAverage patient ageVehicle-treated miceVehicle-treated groupEffect of nintedanibSeverity of fibrosisDevelopment of fibrosisTotal lung collagenSimilar extentNintedanib treatmentLung injuryPatient ageIPF diagnosisClinical efficacyFibrosis severityNintedanib Inhibits Pulmonary Fibrosis Development in Aged Mice but Does Not Reverse Age-Dependent Established Fibrosis
Kato K, Shin Y, Irish J, Rounseville S, Sauler M, Wollin S, Hecker L. Nintedanib Inhibits Pulmonary Fibrosis Development in Aged Mice but Does Not Reverse Age-Dependent Established Fibrosis. 2021, a4425-a4425. DOI: 10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a4425.Peer-Reviewed Original Research